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THE EFFECT OF ONE-TIME PHYSICAL THERAPY ON BIOCHEMICAL MARKERS OF
BONE METABOLISM
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OBJECTIVES: A number of studies suggest that weight-bearing exercises have ben-
eficial effects on bone and increases in BMD of the skeleton. In Hungary 900,000
people suffer from OP, there are 30,000 vertebral fractures, 51,000 other fractures in
a year. The aim of this study was to measure if there is any direct, detected effect of
one specific physiotherapy programme on biomechanical markers of bone
metabolism.METHODS: Total of 50 young, healthy adults (age 252) were included
without any disease or condition of the calcium and bone metabolism (using lab-
oratory tests and Quantitative Ultrasound). Fifteen men and 15 women carried out
specific exercises during 60 min, directed by physiotherapist; and 20 women per-
formed 60 min steady walking in the same time. At the beginning and in the end of
training programs laboratory tests were carried out to measure the level of bone-
specific alkaline phosphate (BALP) and -cross-laps value. Data were analysed by
Wilcoxon tests applying SPSS statistic programme. RESULTS: In both groups a
slight, statistically not significant decrease was detected in the value of BALP
(p0.322 vs. p 0.219; rate of decrease in the target group 3.67%, in control group:
7.16%). Significant decrease was detected in the -cross laps-values in all groups. In
the target group the value of -cross laps decreased with 23.13% (p0.0066), in the
control group with 53.2% (p0.0008). No relationship was found between smoking,
rheumatic diseases run in the family and BMD, but a medium relationship between
regular exercise and BMD could be detected (r0.4392). CONCLUSIONS: This study
proved that the 60-minute, middle intensity, appropriate physiotherapy (even one-
time) has an immediate effect on BALP level, in contrary -cross-laps scores de-
crease significantly measured immediately after the training. So bone loss and at
the same time bone formation started due to mechanical overload.
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OBJECTIVES: Following the introduction of biologic DMARDs, clinicians have now a
multitude of options for the treatment of RA patients with inadequate response to
anti-TNF. This study considers evidence on ACR response from randomised con-
trolled trials of biologic treatments and employs a network meta-analysis to iden-
tify differences amongst them. METHODS: The study considers evidence for the
following treatments: abatacept, anti-TNF, rituximab, and tocilizumab. Pivotal
studies were reviewed and ACR response was extracted for each of the above
treatments. A network meta-analysis using a Bayesian approach was implemented
in WinBUGS®. Fixed-effects and random effects models were explored. Initially,
the development of the study considered all anti-TNF treatments separately.
However, there was limited evidence on ACR response for all of them in the spec-
ified patient subgroup (TNF-IR). This was considered an important factor for treat-
ment efficacy since studies performed on DMARD-IR or MTX-IR population would
include a subgroup of patients with less severe disease. A class effect was assumed
for all anti-TNF and ACR response from Smolen et. al (2009) was assumed to
represent treatment efficacy of all anti-TNFs. RESULTS: For the base-case analysis,
the result shows tocilizumab to have a significant benefit on ACR 20 response of
patients. In ACR 50 all biologics have a similar profile. Rituximab becomes the most
efficacious treatment in ACR 70. CONCLUSIONS: The study demonstrates that as-
suming an indirect comparison of biologics based on a network analysis, tocili-
zumab has better profile than the other biologics in ACR 20 and ACR 50 while
rituximab is better in ACR 70. Further research is needed to produce evidence on
ACR response for all treatments in TNF-IR population.
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THE OSTEOPOROTIC FRACTURE INCIDENCE IN ELDERLY WOMEN OF TAIWAN
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OBJECTIVES: This study aims to investigate the major osteoporotic fractures inci-
dence in Taiwan from 2006 to 2009. METHODS: Using the inpatient and outpatient
database of the National Health Insurance. Elderly Women (50-100 years) who had
primary and secondary diagnosis of hip fracture (ICD9 code 820, 733.14), vertebral
fracture (ICD9 code 805, 806, 733.13), wrist fracture (ICD9 code 813, 733.12), and
other fracture (ICD9 code 807, 808, 810, 811, 812, 821, 823, 733.10, 733.11, 733.15,
733.16, 733.19) were identified and included in the study. Frequencies and inci-
dences of each fracture by age were estimated, and the 4-year incidence trend was
further evaluated. RESULTS:A total of 65,118 hip fractures, the most serious osteo-
porosis outcome, occurred during the study period and the incidence is increasing
by 3-6% per year. We found a high annual incidence rate of clinical vertebral frac-
ture in 4 consecutive years in Taiwan. The average rate was 1.43%, 1.51%, 1.59%,
and 1.63% respectively. In addition, Wrist fracture and other fracture all increased
slightly. Each type of fractures showed a steady increase in the age-adjusted
incidence. CONCLUSIONS: The age-specific incidence rates of hip fractures and
vertebral fractures were higher with increasing age, especially after 60 years of age.
Compared with other countries, Elderly Taiwanese women also have a high inci-
dence rate of hip and vertebral fracture. Our results clearly demonstrated that the
effect of osteoporosis and osteoporotic fracture in Taiwan. We should take more
active public health strategies in the rapidly aging society.
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PREVALENCE OF CLINICAL RISK FACTORS FOR FRACTURES IN THE CANADIAN
MULTICENTRE OSTEOPOROSIS STUDY
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OBJECTIVES: Low bone mineral density (BMD) is one of several important clinical
risk factors (CRFs) for fractures. However, frequency distributions of individual and
multiple CRFs have not been extensively reported. The study aim was to quantify
the CRF profile in a Canadian population. METHODS: Data on CRFs were obtained
from the Canadian Multicentre Osteoporosis Study (CaMos) database, a prospec-
tive and longitudinal cohort study following subjects for over10 years. Subjects
with femoral neck BMD T-scores  1.0 were selected and grouped as osteopenia
(1.0  T-score2.5), osteoporosis [OP] (T-score  2.5), very-low BMD [VLBMD]
(3.5  T-score 2.5), and extremely-low BMD [ELBMD] (T-score  3.5). Fre-
quencies of other CRFs (prevalent fracture, rheumatoid arthritis, glucocorticoid
use, parental hip fracture, smoking status, alcohol consumption, recent falls) were
estimated for BMD T-scores, by age and sex. RESULTS: Among low-BMD women,
2716 (85%) had osteopenia, 491 (15%) had OP; 460 and 31 had VLBMD and ELBMD,
respectively. There were 635 low-BMD men (602, 33, 30, and 3 with osteopenia, OP,
VLBMD, and ELBMD, respectively). OP prevalence increased by age in women
(men): 4% (9%) in age 50-59 to 43% (44%) in age 70-79. In OP women, 21% had 1
previous fracture; 10% had 2. Corresponding values for ELBMD women were 32%
and 52%, respectively. The distribution of multiple CRFs among OP women was:
35%, 43%, 17%, 4%, and 1% for 0-4 additional CRFs. None had over four. In OP
women with prevalent fracture, the distribution was 65%, 29%, 6%, and 1% for 1-4
additional CRFs. CONCLUSIONS:Among the low-BMD population in CaMos, 15% of
women and 5% of men had OP, and over 30% also had prevalent fracture. Over 50%
with OP and prevalent fracture also had at least one additional CRF. These data may
inform estimates on potential fracture incidence and burden in the population.
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PREVALENCE OF SHOULDER OSTEOARTHISTIS AND TREATMENT IN A LARGE
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OBJECTIVES: To estimate the prevalence of shoulder osteoarthritis (OA) and its
treatments. METHODS: Data from Thomson MarketScan (2005-2008), a large na-
tional managed care population database representing more than 500 million em-
ployer-based medical and pharmacy claims were analyzed. Annual prevalence was
calculated as the number of continuously eligible patients who had at least one
shoulder OA diagnosis divided by the total number of continuously eligible pa-
tients. Treatment prevalence was assessed for inpatient shoulder surgery, steroid
injections, physical therapy and pain medication and was calculated as the num-
ber of patients receiving these treatment divided by the number of patients with a
shoulder OA diagnosis. Prevalence percentages were presented descriptively by
age group and overall. RESULTS: There were approximately 20 to 26 million con-
tinuously eligible patients in the data annually between 2005 and 2008. The overall
prevalence of patients with at least one shoulder OA diagnosis was relatively stable
over the years and ranged from 1.1 to 1.2%. In 2008, the shoulder OA prevalence by
age group was: 0 to 18 – 0.01%; 18 to 40 – 0.21%; 40 to 65 – 1.55%; and 65 and
greater – 4.16%. Shoulder surgery was most prevalent in the 40 to 65 age group
(1%), with around 2% prevalence in the 65 and greater age group. Physical therapy
was most common in the 65 year old groups (16.2% to 14.8%), while 65 and older
age group had around 8% prevalence. Steroid injections occurred in 10% of the
patients who were 18 or greater. Use of pain medications increased with age and
ranged by age group from 5% to 36%. CONCLUSIONS: The prevalence of a shoul-
der OA diagnosis was approximately 1.1%, with patients 65 age having the high-
est prevalence (4%). Shoulder OA treatment related resource utilization showed
significant use of drug therapy, physical therapy, and steroid use.
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1South-Trasdanubian Regional Health Insurance Fund Administration, Pécs, Hungary,
2University of Debrecen, Debrecen, Hungary, 3University of Pécs, Pécs, Hungary
OBJECTIVES: The aim of the study is to evaluate the risk factors of second hip and
femur fractures in patients aged over 60 years after initial hip fractures.METHODS:
In this retrospective study the data derive from the financial database of the Hun-
garian National Health Insurance Fund Administration. The study includes pa-
tients over 60 years following primary treatment of femoral neck fracture (S7200)
discharged from inpatient care institutions in 2000. Fractures that happened in
hospitals were excluded from the analysis. The follow up period was 8 years. We
evaluated data according to sex, age group, type of living place, type of hospital
treated the primary fracture, type of primary femoral neck fracture, absence or
presence of comorbidities, type of surgical intervention for primary fracture, and
antiosteoporotic pharmacologic treatment after primary fracture. The effects of
prognostic factors were evaluated by Cox proportional hazard regression analysis
(HR, 95 % CI, p). RESULTS: Altogether 3638 patients were included into the study.
During the observation period 323 second hip fracture (8,87 %) were identified. The
following predictors (hazard ratios and p values) are listed: Sex (female/male):
1.516(0.010); Age group (70-79/60-69y): 1.350(0.058); (80-89/60-69y): 1.496(0.020);
(90y-/60-69y): 1.666(0.067); Residency (capital/village): 1.445(0.072); (city/village):
1.022(0.888); (big city/village): 1.238(0.219); Hospital (capital/county): 0.970(0.878);
(city/county): 1.228(0.156); (clinic/county): 1.105(0.598); Fracture type (lateral/dis-
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placed): 0.929(0.712); (undisplaced/displaced): 0.847(0.249); Comorbidities (no/yes):
0.963(0.836); Surgical types (arthroplasty/osteosynthesis): 1.405(0.026); Antiosteo-
porotic treatment (2years/none): 0.512(0.006); (2years/none): 0.529 (0.004).
CONCLUSIONS: The risk of second hip fracture in elderly 8 year follow up period
was the highest in female, in older age-group, in patient after arthroplasty and in
patient without pharmacologic treatment for osteoporosis. The effect of single risk
factors on the risk of subsequent hip fractures should be investigated in the future.
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ESTABLISHING THE SAFETYOF TUMOURNECROSIS FACTOR INHIBITION (TNF-I) IN
RHEUMATOID ARTHRITIS (RA) FROMANANALYSIS OF REALWORLDDATA
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OBJECTIVES: To perform a systematic review of prospective observational studies
in patients with RA to examine the safety of TNF-I in daily practice, with particular
focus on malignancy, and serious and opportunistic infections. METHODS: Com-
prehensive searches of Medline, Embase, the Cochrane Database of Systematic
Reviews, and ACR, EULAR and BSR conference abstracts were performed according
to a pre-specified protocol that excluded randomised controlled trials. Type and
site of malignancies, as well as serious and opportunistic infections, such as tuber-
culosis, were extracted. Publications that reported incidence rates, standardised
incidence ratios or measures of relative risk, such as incidence rate ratios, odds
ratios or hazard ratios, were selected for random effects meta-analyses. RESULTS:
A total of 2039 papers and 1979 abstracts were identified, of which 48 and 21 re-
spectively met the pre-specified inclusion criteria. The pooled estimate for the
relative risk (RR) of overall malignancy from seven studies was 0.94 (95% CI 0.84,
1.05; I2  0.0%). In contrast, the meta-analysis of serious infections had much
higher heterogeneity, I2 40.9%, RR 1.34 (95% CI 1.06, 1.62). CONCLUSIONS: This
review included data from European, US and Japanese studies with 130,000 pa-
tient years of exposure. Data from such a large number of patients, often with
extended follow-up, overcomes the weaknesses of clinical trial data, specifically
fewer patient numbers and usually shorter exposure times. Observational data has
known weaknesses related to non-randomisation such that statistical techniques
have to be used to overcome differences between the exposed and reference co-
horts. Despite such confounding factors, consideration of the available evidence
leads to the conclusion that there is an increased risk of serious and opportunistic
infections with TNF-I, although no evidence of increased the risk of malignancy.
Meta-analyses of randomised controlled trials have come to different conclusions
regarding both the risk of infections and of malignancy.
Muscular-Skeletal Disorders – Cost Studies
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A BUDGET IMPACT MODEL FOR THE USE OF ABATACEPT AS A FIRST BIOLOGIC
TREATMENT FOR RHEUMATOID ARTHRITIS IN ITALY
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OBJECTIVES:Objective of the study was the budget impact analysis (BIA) of the use
of abatacept as first biologic line for rheumatoid arthritis (RA) patients in Italy.
METHODS: The BIA was based on a Markov model with 6-months cycles and
3-years time horizon. The target population, formed by RA patients starting a first
biologic treatment, was estimated based on RA prevalence and market share data
for biologic drugs. The sequence including abatacept (ABA) as first line was com-
pared with two more traditional sequences of anti-TNF (IFXinfliximab;
ETNetanercept; ADAadalimumab) and rituximab (RTX). The compared se-
quences were: ABA-IFX-RTX; ETN-IFX-RTX; ADA-IFX-RTX. The switch between
treatments for intolerance, adverse events or lack of efficacy was simulated on the
basis of data from RCTs. The disease progression was classified with the ACR
(American College of Rheumatology) I, II, III and IV functional states. Treatments
efficacy was obtained from published RCTs as average reduction of the Health
Assessment Questionnaire (HAQ) score. The HAQ score was then correlated with
the ACR states. Direct costs were valued in the perspective of the Italian health care
system and classified in purchasing, administration and patients routine manage-
ment (visits, exams, hospital stay and other drugs). RESULTS: Italian target popu-
lation was estimated in about 7000 RA patients. At the end of the third year patients
still on first biologic drug were 5670, 4610, and 4680 in the sequence with ABA, ETN
and ADA. Patients in ACR I or II were 6240, 6160 and 6000 respectively. The annual
cost at the third year was €47.0 million, €48.5 million and €47.8 million for the
sequence with ABA, ETN and ADA respectively. CONCLUSIONS: The use of ABA as
first biologic line treatment for RA showed to provide better control of the disease
along with a positive impact in total costs, when compared with traditional se-
quences based on anti-TNF in Italy.
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OBJECTIVES: Data about the burden of JIA are necessary to allocate health care
resources. METHODS: Records were examined for 6 months retrospectively. Bur-
den of JIA in Russia was gotten by summarizing direct and indirect medical costs of
all patients with JIA. The total number of JIA patients and annualized costs were
calculated based on extrapolation method. RESULTS: Data on 405 patients were
obtained. Group with biologics included 124 patients(30.6%), without biologics –
269(66.4%), data about 9(3%) persons were absent. Among 6 biologics used in Russia
for JIA treatment (Abatacept, Adalimumab, Etanercept, Infliximab, Rituximab and
Tocilizumab), costs of biologics and total costs per patient were the smallest in case
of Etanercept – 5,131 USD and 6,967 USD and the biggest with Rituximab - 19,530
USD and 21,944 USD. One-year direct costs per patient with biologics were 36,065
USD. One-year direct costs per patient without biologics was 3149 USD. Average
one-year indirect costs were the same for patients with and without biologics -
1442 USD. Total number of patients with JIA in 2010 was 18,626 people, only 930(5%)
(data of National Center for Child Health of Russian Academy of Medical Sciences,
Moscow, Russia) received biologics. One-year direct costs of all patients with JIA -
89,491,976 USD; indirect costs - 27,491,976 USD; the burden of JIA -116,754,031 USD.
CONCLUSIONS: In 2010 total number of patients with JIA in Russia was estimates
as 18,626 people; burden of JIA was 116,754,031 USD.
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COST OF ETANERCEPT, ADALIMUMAB, AND INFLIXIMAB PER TREATED
PATIENT ACROSS ADULT INDICATIONS USING REAL-WORLD DATA
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OBJECTIVES: To estimate the annual cost of etanercept, adalimumab and inflix-
imab per treated patient across adult indications using drug utilization from a US
managed care population.METHODS:MarketScan Commercial Database was used
to identify all adult patients (18-64 years) with 1 claim for etanercept, adali-
mumab, or infliximab between November 1, 2005-June 6, 2009 who were biologic-
naïve or continuing TNF-blocker treatment (i.e., received a TNF-blocker before the
first (index) claim in the study period) and had a diagnosis for rheumatoid arthritis,
psoriasis, psoriatic arthritis, or ankylosing spondylitis. Patients were required to be
continuously enrolled for 6-months pre-index and 1-year following the index
claim. Patients with Crohn’s disease, or ulcerative colitis in the pre-index period
were excluded. Mean monthly dose was calculated for the 3 TNF-blockers for a
12-month period while patients were on therapy. Wholesale acquisition costs and
the Medicare Physician Fee Schedule were applied to the mean monthly dose and
related drug administration to estimate TNF-blocker cost per treated patient.
RESULTS: Overall, 12,065 etanercept, 5,685 adalimumab, and 3,902 infliximab pa-
tients were included. Biologic-naïve patients consisted of 43% of patients. Patient
characteristics were similar across treatment groups with a mean age (SD) of 49 (10)
years and 66% female. The mean annual TNF-blocker cost per treated patient for all
patients was $14,446 for etanercept, $18,000 for adalimumab, and $23,348 for inf-
liximab. In biologic-naïve patients, the TNF-blocker cost per treated patient was
$13,703 for etanercept, $16,932 for adalimumab, and $20,500 for infliximab; in pa-
tients continuing treatment it was $14,901 for etanercept, $19,410 for adalimumab,
and $25,028 for infliximab. CONCLUSIONS: Patients receiving etanercept had the
lowest TNF-blocker cost per treated patient for adult indications when using actual
drug utilization from a US managed care population. TNF-blocker costs per treated
patient on adalimumab and infliximab, respectively are approximately 25% and
62% higher than etanercept.
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OBJECTIVES: To describe annual costs of etanercept, adalimumab and infliximab
per treated patient across adult indications using real-world US drug data.
METHODS: IMS LifeLink™ Health Plan Claims database was used to identify adult
patients (18y) with 1 claim for etanercept, adalimumab or infliximab between
January 1, 2005-March 31, 2009 (first TNF-blocker claim in study period is index
claim); patients who were biologic-naïve or continuing TNF-blocker treatment
were included. Patients had to have 360 days continuous enrollment following
index claim and 180 days prior to index claim (pre-index period). In the pre-index
period, patients were included if they had a diagnosis of rheumatoid arthritis,
psoriasis, psoriatic arthritis, or ankylosing spondylitis, but were excluded if they
had a diagnosis of Crohn’s disease or ulcerative colitis. Patients were followed for
1-year. Mean monthly dose was computed for patients on therapy; wholesale ac-
quisition costs were applied to mean monthly dose and Medicare Physician Fee
Schedule was applied to related drug administrations. Costs from restarting index
TNF-blocker therapy after discontinuation and costs from switching to a different
TNF-blocker were attributed to patients’ index therapy. RESULTS: Overall, 27,704
patients (14,777 etanercept, 6,862 adalimumab, 6,065 infliximab), were identified.
The indication mix was 65% rheumatoid arthritis, 11% psoriasis, 13% psoriatic
arthritis, 5% ankylosing spondylitis, and 6% with multiple indications. The 1-year
mean cost per treated patient for all patients was lowest for etanercept, $14,013,
followed by adalimumab, $17,716, then infliximab, $20,665. For biologic-naïve pa-
tients, mean cost per treated patient was $13,342 for etanercept, $16,718 adali-
mumab, and $18,589 infliximab. For patients continuing biologic therapy, cost per
treated patient was $14,438 for etanercept, $18,816 adalimumab, and $21,846
infliximab. CONCLUSIONS: When comparing TNF-blocker cost per treated patient
across adult indications, etanercept has the lowest cost per treated patient com-
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